Adaptimmune Therapeutics plc (ADAP) |
|
1.1 0 (0%)
|
03-27 16:00 |
|
Open: |
1.11 |
Pre. Close: |
1.1 |
|
High:
|
1.14 |
Low:
|
1.1 |
|
Volume:
|
304,752 |
Market Cap:
|
182(M) |
|
|
|
Technical analysis |
as of: 2023-03-27 4:17:06 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 1.79 One year: 2.16 |
| Support: |
Support1: 1.01 Support2: 0.84 |
| Resistance: |
Resistance1: 1.53 Resistance2: 1.85 |
| Pivot: |
1.14  |
| Moving Average: |
MA(5): 1.11 MA(20): 1.26
MA(100): 1.68 MA(250): 1.69 |
| MACD: |
MACD(12,26): -0.2 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 16.4 %D(3): 12.8 |
| RSI: |
RSI(14): 36.1 |
| 52-week: |
High: 2.65 Low: 1 |
| Average Vol(K): |
3-Month: 550 (K) 10-Days: 697 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ADAP ] has closed above bottom band by 27.6%. Bollinger Bands are 74.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.12 - 1.13 |
1.13 - 1.13 |
|
Low:
|
1.05 - 1.05 |
1.05 - 1.06 |
|
Close:
|
1.09 - 1.1 |
1.1 - 1.11 |
|
Company Description |
|
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic T-cell therapies utilizing aß T-cell receptors. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom. |
Headline News |
Mon, 27 Mar 2023
STOCKHOLDER ALERT: The M&A Class Action Firm Continues its ... - Digital Journal
Mon, 27 Mar 2023
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Receives $6.12 ... - Defense World
Sun, 26 Mar 2023
Bryan, Garnier & Co. has initiated coverage of Adaptimmune ... - Best Stocks
Sat, 25 Mar 2023
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Receives ... - MarketBeat
Thu, 23 Mar 2023
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ... - Benzinga
Wed, 08 Mar 2023
New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP) - Simply Wall St
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
165 (M) |
| Shares Float |
97 (M) |
|
% Held by Insiders
|
0.1 (%) |
|
% Held by Institutions
|
70.1 (%) |
|
Shares Short
|
2,890 (K) |
|
Shares Short P.Month
|
2,800 (K) |
Stock Financials |
|
EPS
|
-0.98 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0.5 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-595.6 |
|
Return on Assets (ttm)
|
-25.4 |
|
Return on Equity (ttm)
|
-115 |
|
Qtrly Rev. Growth
|
678.2 |
|
Gross Profit (p.s.)
|
-0.61 |
|
Sales Per Share
|
0.16 |
|
EBITDA (p.s.)
|
-0.95 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-142 (M) |
|
Levered Free Cash Flow
|
-110 (M) |
Stock Valuations |
|
PE Ratio
|
-1.14 |
|
PEG Ratio
|
-2.3 |
|
Price to Book value
|
2.2 |
|
Price to Sales
|
6.69 |
|
Price to Cash Flow
|
-1.29 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2018-03-29 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
